Latest Regulatory Risks News

Count Limited has successfully raised $35.9 million through an institutional placement to partially fund its acquisition of Oracle Group Ltd, while also launching a $5 million Share Purchase Plan for existing shareholders.

Fiducian Investment Management Services Limited has reached a heads of agreement with ASIC to resolve civil proceedings over misleading disclosures in its Diversified Social Aspirations Fund. The settlement includes a $7.3 million penalty and legal costs, pending court approval.

Kjerulf David Hastings Ainsworth has initiated a second unconditional off-market takeover bid for 5.5% of Ainsworth Game Technology shares at a significant premium, aiming to increase his stake and influence in the company.

AdAlta’s subsidiary AdCella has completed its first Joint Development Committee meeting with Shanghai Cell Therapy Group, advancing the development of the CAR-T therapy BZDS1901 with potential timeline acceleration and reduced regulatory risks.

Reach Resources Limited has announced a pro-rata entitlement issue aiming to raise up to $3.15 million to fund exploration and working capital, with key directors and the CEO committing to participate.

Manuka Resources has released an amended Pre-Feasibility Study for its Cobar Basin assets, revealing a significant uplift in project profitability and a detailed 10-year mine plan targeting production in Q2 2026.

Nexsen Limited has successfully completed a pivotal FDA Pre-Submission meeting for its StrepSure® diagnostic, significantly reducing regulatory risks and advancing its entry into the large US maternal health market.

Ovanti Limited launches its One Financial Superapp powered by Isentric, combining instant payments, DeFi yields, BNPL, and AI financial advisory in a unified platform targeting underbanked markets.

The Brazilian government has imposed a 12% tax on crude oil exports effective immediately, a move framed as windfall profit sharing amid high oil prices. Karoon Energy, with significant Brazilian operations, faces new cost pressures as the tax awaits potential ratification by Congress.

The South Australian Court of Appeal has overturned a 2023 government proclamation, returning the Bird in Hand Gold deposit to Terramin’s exploration licence and reshaping the company’s exploration prospects.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals is seeking a re-examination of the European Medicines Agency’s refusal to approve trofinetide for Rett syndrome, aiming to overturn the setback and bring the treatment to European patients.

ABx Group’s maiden mixed rare earth carbonate from Tasmania’s Deep Leads resource has been confirmed radiologically safe by ANSTO, with a second, higher-grade sample expected soon. The development could open doors to key international customers and reduce regulatory complexities.